Tempest Therapeutics, Inc. 8-K

What Happened
Tempest Therapeutics, Inc. (TPST) filed a Form 8-K on May 22, 2026, reporting that three members of its Board of Directors—Stephen Brady, Michael Raab and Christine Pellizzari—resigned from the board effective May 22, 2026. The company stated it has not been informed that the resignations were due to any disagreement with the company regarding its operations, policies or practices.

Key Details

• Filing: Form 8-K dated May 22, 2026 (Item 5.02: Departure of Directors or Certain Officers).
• Resignations effective: May 22, 2026.
• Directors who resigned: Stephen Brady, Michael Raab, Christine Pellizzari.
• Company statement: No notice that resignations resulted from disagreements with the company on operations, policies or practices.

Why It Matters
Board departures can affect corporate governance and investor confidence. This filing is a factual disclosure of personnel changes; the company did not indicate any dispute or reason tied to its operations. Investors should note the change in board composition and watch for any future filings or announcements about new board appointments or potential impacts on strategy.